Another Reason To Watch Kite's CAR-T Results At ASH
This article was originally published in Scrip
Executive Summary
Kite Pharma CEO Arie Belldegrun confirmed on Aug. 17 that a patient died soon after treatment with the company's chimeric antigen receptor T-cell (CAR-T) therapy during the Phase I portion of an ongoing Phase I/II clinical trial, but he said the death was not related to Kite's closely-watched cancer therapy.